Save 25% with code AUTUMN25 at checkout.

Join the Defiants

Sign up to be the first to know about special offers and exciting Signos news.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
October 20, 2026
|
Weight Loss
|
3 min read
|
Written By
Signos Staff

Is It Harder for Women to Lose Weight Than Men? What the Science Says

A man and a woman start trying to lose weight at the same time. Same dietary changes, same activity increase, same consistency. A few weeks later, his scale is moving faster. Hers barely seems to budge.

‍

It's a frustrating enough pattern that it has become almost a cliché. But is that actually what the science shows? The answer is more nuanced than most people expect, and in some cases, it's not what you'd predict.

Do Men Lose Weight Faster Than Women?

On average, men may lose weight faster than women in some interventions, particularly early on. But that doesn't mean women are biologically less capable of achieving comparable long-term fat loss.

‍

Observed differences often reflect overlapping factors: men tend to have larger bodies, more lean mass, and higher total daily energy expenditure. Comparing pounds lost also obscures a lot. A 220-pound man losing 10% drops 22 pounds. A 150-pound woman losing the same 10% drops 15 pounds. The scale makes the man's loss look dramatically larger when both lose the same proportion of their starting weight.

‍

The picture becomes more interesting when you look at GLP-1 medications specifically. A 2024 study of 1,039 patients at the Mayo Clinic found that women achieved significantly greater total body weight loss percentage than men after 15 months of tirzepatide treatment, 15.1% versus 10.7%.¹ Men may have an average advantage in how quickly pounds come off in lifestyle interventions, but that is not the same as saying women cannot lose weight as effectively.

Why Do Men Often Lose Weight Faster Than Women?

The biggest contributor isn't a "faster metabolism" in the way most people mean it. Men typically begin with larger bodies, more lean mass, larger organs, and greater skeletal muscle, all of which contribute to higher total daily energy expenditure. When someone with a 2,700-calorie daily energy requirement creates a calorie deficit, the absolute deficit is larger than when someone with a 1,900-calorie requirement makes the same percentage cut. That translates into faster scale movement.

‍

Notably, a 2025 study in the Journal of the International Society of Sports Nutrition found no statistically significant difference in the time it took men and women to lose 5% of body weight when protein intake was standardized at 1.6g per kilogram of body weight.² The practical implication: protein intake and calorie deficit matter more than sex when conditions are equalized.

How Do Muscle Mass and Metabolism Affect Weight Loss in Women vs. Men?

Muscle requires energy to maintain, so more lean mass means higher resting energy expenditure. But muscle matters beyond calories. Skeletal muscle is one of the body's primary sites for glucose disposal after eating, which means more muscle supports better insulin sensitivity and blood sugar stability.

‍

For women, trying to lose weight through aggressive calorie restriction while ignoring muscle can work against long-term outcomes. If weight loss includes significant lean-mass loss, body weight drops but so does strength, glucose-disposal capacity, and resting metabolic rate. A 2024 systematic review and meta-analysis of 47 randomized controlled trials in Clinical Nutrition ESPEN found that higher protein intake significantly prevented muscle mass decline during weight loss in adults with overweight and obesity.³

‍

For women, protecting and building muscle is one of the most powerful levers for improving body composition and metabolic health during weight loss.

How Do Hormones Affect Weight Loss in Women?

Female hormones influence weight regulation in real and measurable ways without being a catch-all explanation for every plateau.

‍

Estrogen plays a key role in fat distribution, insulin sensitivity, and appetite regulation. Before menopause, estrogen promotes fat storage subcutaneously (hips, thighs, buttocks) rather than viscerally (around the organs), and enhances insulin sensitivity (ie, helps your body use glucose for fuel more effectively). Progesterone rises after ovulation and may increase appetite and energy expenditure, while altering how the body handles carbohydrates due to a decline in insulin sensitivity, particularly in the luteal phase.

‍

Fat loss can also be harder to see on the scale during certain phases of the menstrual cycle.. Hormonal shifts temporarily alter water retention, sodium balance, and glycogen storage, creating scale changes of several pounds within a single week that have nothing to do with body fat. Someone can be successfully losing fat while the scale barely moves or temporarily increases.

‍

Female hormones don't make fat loss impossible, but they do change appetite, glucose regulation, fluid balance, and what progress looks like week to week. This is why comparing daily and weekly scale numbers can be genuinely misleading, and why tracking a longer-term trend or using body composition data gives a much more accurate picture of what's actually happening. Try tracking your body composition, waist circumference, and how your clothes are fitting every 3-4 weeks instead of relying on the scale week by week. 

Why Is It Harder to Lose Weight During Perimenopause and Menopause?

As estrogen declines during the menopause transition, body composition shifts in ways that make weight management more challenging. A 2021 study in Scientific Reports found that postmenopausal women had approximately 18% more visceral fat than premenopausal women for a given total fat mass, alongside lower estimated insulin sensitivity.⁴ The scale may look similar while the metabolic picture underneath has changed significantly.

‍

This matters because visceral fat (stored around internal organs) carries more cardiometabolic risk than subcutaneous fat. Menopause also doesn't happen independently of aging. For women going through the transition, aging-related muscle loss and hormonal changes can compound simultaneously. 

‍

Disrupted sleep, which is extremely common during this transition, compounds the picture further: poor sleep independently raises hunger hormones, reduces insulin sensitivity, and makes body composition harder to maintain, often at the exact moment when other hormonal changes are already working against you.

‍

The most useful shift for women in this transition isn't eating less and exercising more. It's changing what you're optimizing for: less focus on the scale, more focus on building and retaining muscle, prioritizing sleep as a metabolic lever, and tracking body composition alongside weight so you can see what's actually changing, not just what a number says.

Does PCOS Make It Harder to Lose Weight?

For women with polycystic ovary syndrome (PCOS), which affects 10-15% of women of reproductive age, weight loss has an additional biological layer that standard advice often misses.⁵

‍

PCOS creates insulin resistance, meaning the body's cells don't respond normally to insulin's signal to absorb glucose from the bloodstream. The pancreas compensates by producing more insulin, and that excess insulin then signals the ovaries to produce more androgens (male-type hormones like testosterone), which promotes abdominal fat storage and worsens insulin resistance further. This cycle is intrinsic to the condition: research indicates that up to 75% of lean women with PCOS have insulin resistance, rising to as high as 95% in those with obesity.⁵ The practical result is that the same calorie deficit that produces consistent weight loss in a woman without PCOS may produce slower or less predictable results in a woman with it.

‍

The encouraging part: even a small 5-10% reduction in body weight in overweight or obese women with PCOS has been shown to improve insulin sensitivity, reduce androgens, and restore regular menstrual cycles. GLP-1 medications are also showing early promise, with a 2025 review in Current Obesity Reports finding new evidence they can improve weight, insulin sensitivity, and menstrual regularity in women with PCOS, though larger trials are still needed.⁵

‍

Resistance training, adequate protein, and tracking body composition and glucose patterns tend to give a more complete, honest picture of progress than scale weight alone in this population especially. 

Do Women and Men Store and Lose Body Fat Differently?

Before menopause, women tend to store fat subcutaneously around the hips and thighs. Men tend to accumulate fat centrally and viscerally. After menopause, women's distribution shifts toward a more central, visceral pattern.

‍

The body determines where fat comes off first, and spot reduction doesn't work. Two people can lose the same number of pounds but lose very different proportions of fat, lean mass, visceral fat, and water. The scale number alone tells you almost nothing about the quality of the weight loss.

How Can Women Lose Weight More Effectively?

Prioritize fat loss, not just weight loss. Useful markers beyond the scale include waist circumference, strength, body composition, energy, and glucose patterns.

‍

Build and protect muscle. Progressive resistance training should be a centerpiece, not an accessory. It supports glucose disposal, insulin sensitivity, and long-term body composition in ways cardio alone cannot.

‍

Eat enough protein. Higher protein intakes (around 1.2 to 1.6g per kilogram of body weight daily) have been shown to preserve lean mass during weight loss.³ Distribute protein meaningfully across meals rather than concentrating it at dinner.

‍

Avoid unnecessarily aggressive calorie deficits. Extreme restriction makes it harder to train, preserve muscle, manage hunger, and sustain the plan long enough to matter.

‍

Adjust strategies as physiology changes. A plan that worked at 30 may not be optimal at 45 or 50. Changes in muscle mass, sleep, hormones, and glucose regulation all warrant revisiting strategy rather than assuming that needing a different approach means something went wrong.

How Should Women Measure Weight Loss Beyond the Scale?

A scale cannot tell you how much fat you lost, whether you preserved muscle, whether visceral fat improved, or how your insulin sensitivity changed. Weight is one signal. It's not the most complete one.

‍

Body composition tracking lets you ask not just whether weight changed, but what that change is made of. A CGM adds another layer: how meal composition, post-meal movement, sleep, exercise, and hormonal shifts influence your individual glucose responses. For women navigating the menstrual cycle, perimenopause, or menopause, glucose patterns can surface information about how those hormonal changes are affecting metabolism in real time.

‍

The goal isn't more numbers. It's a better signal: understanding whether the changes you're making are actually moving your metabolic health in the right direction for your specific body, at this specific stage of life.

Topics discussed in this article:

References

  1. Castaneda, R., Bechenati, D., Rivera Gutierrez, R. de J., et al. (2026). Sex, not age, predicts weight loss outcomes with tirzepatide: A retrospective analysis. Obesity, 34(Suppl 2), 132–145. https://doi.org/10.1002/oby.70231
  2. Rodriguez Da Silva, V., Singh, R., Silva Ramirez, V. V., et al. (2025). Comparing weight loss rates between males and females: A preliminary analysis. Journal of the International Society of Sports Nutrition, 22(Suppl 2), 2550187. https://doi.org/10.1080/15502783.2025.2550187
  3. Kokura, Y., Ueshima, J., Saino, Y., & Maeda, K. (2024). Enhanced protein intake on maintaining muscle mass, strength, and physical function in adults with overweight/obesity: A systematic review and meta-analysis. Clinical Nutrition ESPEN, 63, 417–426. https://doi.org/10.1016/j.clnesp.2024.06.030
  4. Abildgaard, J., Ploug, T., Al-Saoudi, E., et al. (2021). Changes in abdominal subcutaneous adipose tissue phenotype following menopause is associated with increased visceral fat mass. Scientific Reports, 11, 14750. https://doi.org/10.1038/s41598-021-94189-2
  5. Diakosavvas, M., Oyebode, O., & Bhide, P. (2025). Weight management strategies to reduce metabolic morbidity in women with polycystic ovary syndrome. Current Obesity Reports, 14, 22. https://doi.org/10.1007/s13679-025-00614-2

‍

Signos Staff

Signos Staff

The Signos team is made up of a medical doctor, certified health coaches, a data scientist, and experienced health, science, and wellness writers.

Table Of Contents
Hands chopping zucchini and tomatoes on a colorful cutting board

Your body runs on glucose. Harness it with Signos.

As seen in:

SIGNOS INDICATIONS: The Signos Glucose Monitoring System is an over-the-counter (OTC) mobile device application that receives data from an integrated Continuous Glucose Monitor (iCGM) sensor and is intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. The Signos Glucose Monitoring System helps to detect normal (euglycemic) and low or high (dysglycemic) glucose levels. The Signos Glucose Monitoring System may also help the user better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursions. This information may be useful in helping users to maintain a healthy weight.
The user is not intended to take medical action based on the device output without consultation with a qualified healthcare professional.
See user guide for important warnings and precautions.

STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency.

STELO INDICATIONS FOR USE: The Stelo Glucose Biosensor System is an over-the-counter (OTC) integrated Continuous Glucose Monitor (iCGM) intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. The Stelo Glucose Biosensor System helps to detect normal (euglycemic) and low or high (dysglycemic) glucose levels. The Stelo Glucose Biosensor System may also help the user better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursion. The user is not intended to take medical action based on the device output without consultation with a qualified healthcare professional.

OPENLOOP CLINICAL AND PHARMACEUTICAL SERVICES:

Signos is a technology platform and wellness program provider. With the exception of registered dieticians, Signos does not employ licensed health care professionals to practice medicine, does not diagnose, treat, cure, or prevent any disease or medical condition, and does not provide medical advice. You should always consult your own health care professional for diagnosis, treatment, and care regarding any medical condition or health concern. Clinical services accessible through the Signos platform are provided solely by OpenLoop Health and other independent networks of U.S.-licensed clinicians, who exercise their own independent medical judgment to determine eligibility for GLP‑1 treatment based on medical history and assessment responses. These independent providers retain full discretion to prescribe or decline compounded GLP‑1 medications. Signos does not direct, control, or influence any clinical decision made by these providers, and no provider-patient relationship is created between you and Signos.

Compounded medications that may be made available in connection with the Signos program are produced in FDA-registered facilities, but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. Signos does not manufacture, compound, dispense, or distribute any medications. Signos partners with certified U.S. pharmacies to help facilitate access to these medications, but Signos makes no representations or warranties regarding the safety, efficacy, suitability, or quality of any compounded medication. Product appearance may differ from website images.

Medication costs are included in the Signos program; however, inclusion of medication costs does not constitute the practice of medicine or pharmacy by Signos. Results may vary and depend on individual adherence, independent provider guidance, and lifestyle changes. Unless otherwise noted, results referenced reflect individual Signos patient experiences rather than public clinical studies, and no particular outcome is guaranteed.

Nothing on this website or within the Signos platform should be construed as medical advice, a medical diagnosis, or a recommendation for any specific treatment. If you are experiencing a medical emergency, call 911 or your local emergency services immediately.